MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.
作者： Zhibin Hu , Jiaping Chen , Lingmin Hu , Juncheng Dai , Guangfu Jin
DOI: 10.1002/MC.20727
关键词:
摘要: Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene p53. Single nucleotide polymorphisms in MDM2 and p53 can affect patient's response to chemotherapy as well overall survival many cancers. This study aimed assess associations between non-small cell lung cancer (NSCLC) patients Chinese. We selected genotyped both potentially functional SNPs tagging using Illumina Golden Gate platform cohort 568 NSCLC patients. Associations genotypes median time (MST) were assessed Kaplan–Meier method. Cox proportional hazard models performed with adjustment for age, stage, smoking, histology, surgical operation, chemo- or radiotherapy status. found that SNP309 (rs2279744) GT/TT associated significantly worse (MST: 23.0 mo vs. 33.0 mo GG; log-rank P = 0.028). In multivariate regression analyses, SNP309GT/TT 1.42-fold [HR = 1.42, 95% confidence interval (CI), 1.09–1.84] increased risk death NSCLC, compared SNP309GG genotype. may be used one candidate biomarkers predict survival. © 2011 Wiley-Liss, Inc.
sci-hub.se 参考文章(37)
Arnold J. Levine, Shengkan Jin, The p53 functional circuit. Journal of Cell Science. ,vol. 114, pp. 4139- 4140 ,(2001) , 10.1242/JCS.114.23.4139
Wen-Pin Chien, Ruey-Hong Wong, Ya-Wen Cheng, Chih-Yi Chen, Huei Lee, Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors Annals of Surgical Oncology. ,vol. 17, pp. 1194- 1202 ,(2010) , 10.1245/S10434-009-0853-2
Gareth L. Bond, Wenwei Hu, Arnold Levine, A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Research. ,vol. 65, pp. 5481- 5484 ,(2005) , 10.1158/0008-5472.CAN-05-0825
Zhi-Xlong Xiao, Jiandong Chen, Arnold J. Levine, Nazanlne Modjtahedi, Jun Xing, William R. Sellers, David M. Livingston, Interaction between the retinoblastoma protein and the oncoprotein MDM2 Nature. ,vol. 375, pp. 694- 698 ,(1995) , 10.1038/375694A0
Klaus Martin, Didier Trouche, Christian Hagemeier, Troels S. Sorensen, Nicholas B. La Thangue, Tony Kouzarides, Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. ,vol. 375, pp. 691- 694 ,(1995) , 10.1038/375691A0
Ji-Youn Han, Geon Kook Lee, Dae Ho Jang, Sung Young Lee, Jin Soo Lee, Association ofp53codon 72 polymorphism andMDM2SNP309 with clinical outcome of advanced nonsmall cell lung cancer Cancer. ,vol. 113, pp. 799- 807 ,(2008) , 10.1002/CNCR.23668
David Malkin, Kent W. Jolly, Noële Barbier, A. Thomas Look, Stephen H. Friend, Mark C. Gebhardt, Tone I. Andersen, Anne-Lise Børresen, Frederick P. Li, Judy Garber, Louise C. Strong, Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. The New England Journal of Medicine. ,vol. 326, pp. 1309- 1315 ,(1992) , 10.1056/NEJM199205143262002
Sandra L Harris, Arnold J Levine, The p53 pathway: positive and negative feedback loops Oncogene. ,vol. 24, pp. 2899- 2908 ,(2005) , 10.1038/SJ.ONC.1208615
D. R. Brown, The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell‐cycle‐inhibitory function induces tumorigenesis The EMBO Journal. ,vol. 17, pp. 2513- 2525 ,(1998) , 10.1093/EMBOJ/17.9.2513
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74